Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair
follicle associated infiltration and improve hair growth.
This is a double blind placebo controlled study to test the safety and efficacy of Abatacept
in the treatment of 64 subjects diagnosed with alopecia totalis or alopecia universalis.
Subjects will be randomized 1:1 to the placebo or treatment arm and will receive 6 months of
treatment with the study medication or placebo, followed by a 6 month observational period.